19786-48-2

Basic information

• Product Name: (4-Nitrophenoxy)acetic acid methyl ester
• Synonyms: (4-Nitrophenoxy)acetic acid methyl ester;4-Nitrophenoxyacetic acid methyl ester
• CAS NO: 19786-48-2
• Molecular Formula: C₉H₉NO₅
• Molecular Weight: 211.18
• Mol File: 19786-48-2.mol

Chemical Properties

• Melting Point: 99 °C
• Boiling Point: 337.4±17.0 °C(Predicted)
• Appearance: /
• Density: 1.305±0.06 g/cm3(Predicted)
• CAS DataBase Reference: (4-Nitrophenoxy)acetic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (4-Nitrophenoxy)acetic acid methyl ester(19786-48-2)
• EPA Substance Registry System: (4-Nitrophenoxy)acetic acid methyl ester(19786-48-2)

Safety Data

• Hazardous Substances Data: 19786-48-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
(4-Nitrophenoxy)acetic acid methyl ester is used as an intermediate in the synthesis of isotopically labeled analogues of pharmaceutical compounds. It plays a vital role in the production of 2-(4-(Methylsulfonamido)phenoxy)acetic Acid-13C (M332217), which is an isotopically labeled analogue of 2-(4-(Methylsulfonamido)phenoxy)acetic Acid (M332215). This metabolite is derived from the antiarrhythmic drug Dofetilide (D525700), a potassium channel blocker.
Used in the Synthesis of Dofetilide Metabolites:
(4-Nitrophenoxy)acetic acid methyl ester is used as a key component in the synthesis of metabolites of Dofetilide, an antiarrhythmic drug. This application is significant in the development and understanding of the drug's pharmacokinetics, pharmacodynamics, and potential side effects, as well as in the design of new drugs with improved efficacy and safety profiles.
Used in the Chemical Industry:
In the chemical industry, (4-Nitrophenoxy)acetic acid methyl ester may be utilized as a building block for the synthesis of various organic compounds, including those with potential applications in materials science, agrochemicals, and other specialized fields. Its reactivity and functional groups make it a versatile starting material for the development of new molecules with specific properties and applications.

Upstream product

• 100-02-7 4-nitro-phenol 
• 124-41-4 sodium methylate 
• 105-39-5 chloroacetic acid ethyl ester 
• 96-34-4 methyl chloroacetate 
• 1798-11-4 4-nitrophenoxyacetic acid 
• 96-32-2 bromoacetic acid methyl ester 
• 67-56-1 methanol 
• 20142-88-5 2-(4-nitrophenoxy)acetyl chloride 

Downstream Products

• 1798-11-4 4-nitrophenoxyacetic acid 
• 20485-38-5 ethyl 2-(4-aminophenoxy)acetate 
• 1097212-97-9 N-(2-(3,4-dichlorophenylamino)ethyl)-2-(4-(methylsulfonamido)phenoxy)acetamide 
• 1194838-56-6 N-(3,4-dichlorocinnamyl)-2-(4-(methylsulfonamido)-phenoxy)acetamide 
• 1192366-81-6 N-(3-(3,4-dichlorophenyl)propyl)-2-(4-(methylsulfonamido)phenoxy)acetamide 
• 1192366-83-8 N-(2-(3,4-dichlorophenoxy)ethyl)-2-(4-(methylsulfonamido)phenoxy)acetamide 
• 1192366-85-0 N-(2-(3,4-dichlorophenylthio)ethyl)-2-(4-(methylsulfonamido)phenoxy)acetamide 
• 1097213-03-0 N-(4-(2-(4-(3,4-dichlorophenyl)piperazin-1-yl)-2-oxoethoxy)phenyl)methanesulfonamide 
• 1192366-91-8 N-(3-(3,4-dichlorophenylamino)propyl)-2-(4-(methylsulfonamido)phenoxy)acetamide 
• 103790-20-1 2-(4-(methylsulfonamido)phenoxy)acetic acid 
• 592551-85-4 C₂₄H₂₆FN₃O₃ 
• 592551-84-3 C₂₅H₂₆FN₃O₄ 
• 20916-22-7 N-(4-chlorophenyl)-2-(4-nitrophenoxy)acetamide 

Relevant articles and documents

Rapid and high-yield synthesis of aryloxyacetates under microwave irradiation and phase-transfer catalysis conditions

A series of methyl aryloxyacetates (3a-3f) have been synthesized by the reaction of substituted phenol with methyl chloroacetate under the conditions of microwave irradiation and phase-transfer catalysis. By the optimization of the reaction conditions, we developed a good method for the preparation of methyl aryloxyacetates, which have the advantages of high yields, short reaction times, ease of workup, and simple operation. Copyright Taylor & Francis, Inc.

Selective Janus Kinase 2 (JAK2) Pseudokinase Ligands with a Diaminotriazole Core

Janus kinases (JAKs) are non-receptor tyrosine kinases that are essential components of the JAK-STAT signaling pathway. Associated aberrant signaling is responsible for many forms of cancer and disorders of the immune system. The present focus is on the d

Synthesis and herbicidal activities of aryloxyacetic acid derivatives as HPPD inhibitors

A series of aryloxyacetic acid derivatives were designed and synthesized as 4-hydoxyphenylpyruvate dioxygenase (HPPD) inhibitors. Preliminary bioassay results reveal that these derivatives are promising Arabidopsis thaliana HPPD (AtHPPD) inhibitors, in particular compounds I12 (Ki = 0.011 μM) and I23 (Ki = 0.012 μM), which exhibit similar activities to that of mesotrione, a commercial HPPD herbicide (Ki = 0.013 μM). Furthermore, the newly synthesized compounds show significant greenhouse herbicidal activities against tested weeds at dosages of 150 g ai/ha. In particular, II4 exhibited high herbicidal activity for pre-emergence treatment that was slightly better than that of mesotrione. In addition, compound II4 was safe for weed control in maize fields at a rate of 150 g ai/ha, and was identified as the most potent candidate for a novel HPPD inhibitor herbicide. The compounds described herein may provide useful guidance for the design of new HPPD inhibiting herbicides and their modification.

New: N -phenyl-4,5-dibromopyrrolamides as DNA gyrase B inhibitors

Due to the rapid development of antimicrobial resistance, the discovery of new antibacterials is essential in the fight against potentially lethal infections. The DNA gyrase B (GyrB) subunit of bacterial DNA gyrase is an excellent target for the design of

Histone deacetylase inhibitors and its preparation method and use thereof

The invention discloses a histone deacetylase inhibitor and its preparation method and use, the invention discloses a compound of the formula I as shown, or its crystalline form, or its pharmaceutically acceptable salt, or solvate thereof, or prodrug thereof, or its metabolic product. The invention of the formula I illustrated new compound, has shown good deacetylase inhibition activity, with the histone deacetylase for clinical treatment of diseases associated with abnormal activity of a new pharmaceutical may be.

Design, synthesis and biological evaluation of novel FFA1/GPR40 agonists: New breakthrough in an old scaffold

Based on an old phenoxyacetic acid scaffold, CPU014 (compound 14) has been identified as a superior agonist by comprehensive exploration of structure-activity relationship. In vitro toxicity study suggested that CPU014 has lower risk of hepatotoxicity than TAK-875. During acute toxicity study (5–500 mg/kg), a favorable therapeutic window of CPU014 was observed by evaluation of plasma profiles and liver slices. Moreover, CPU014 promotes insulin secretion in a glucose-dependent manner, while no GLP-1 secretion has been enhanced. Other than good pharmacokinetic properties, CPU014 significantly improved glucose tolerance both in normal and diabetic models without the risk of hypoglycemia. These subversive findings provided a safer candidate CPU014, which is currently in preclinical study to assess its potential for the treatment of diabetes.

Novel Quinazoline Derivatives Bearing Various 4-Aniline Moieties as Potent EGFR Inhibitors with Enhanced Activity Against NSCLC Cell Lines

A class of novel quinazoline derivatives bearing various C-4 aniline moieties was synthesized and biologically evaluated as potent epidermal growth factor receptor (EGFR) inhibitors for intervention of non-small-cell lung cancer (NSCLC). Most of these inhibitors are comparable to gefitinib in inhibiting these cancer cell lines, and several of them even displayed superior inhibitory activity. In particular, analogue 5b with an IC50 of 0.10 μm against the EGFR wild-type A431 cells and 5c with an IC50 of 0.001 μm against the gefitinib-sensitive HCC827 cells (EGFR del E746-A750) was identified as highly active EGFR inhibitors. It was also significant that the discovered analogue 2f, not only has high potency against the gefitinib-sensitive cells (IC50 = 0.031 μm), but also possesses remarkably improved activity against the gefitinib-resistant cells. In addition, the enzymatic assays and the Western blot analysis for evaluating the effects of the typical inhibitors indicated that these molecules strongly interfere with the EGFR target.

Synthesis and molecular structures of 1-hydroxyethyl-2-(p-substituted) phenoxymethyl benzimidazoles

Five novel 1-hydroxyethyl-2-(p-substituted) phenoxymethyl benzimidazoles were synthesized by a three-step route. Under microwave irradiation, the p-substituted phenols were firstly O-carboxymethylated to prepare the corresponding p-substituted phenoxymethyl acids, which then reacted with o-phenylendiamine to get the key intermediates 2-(p-substituted) phenoxymethyl benzimidazole. Finally, the solid-liquid phase transfer catalysis method, where tetrabutyl ammonium bromide (TBAB) was used as the catalyst, was applied to synthesize the target compounds c1-c5 by the N-hydroxyethylation reaction with 2-chloroethyl alcohol. The structures of the obtained compounds were well characterized and confirmed by elemental analysis, MS, IR, 1H NMR, 13C NMR and single-crystal X-ray diffraction analysis.

N-Phenyl-4,5-dibromopyrrolamides and N-Phenylindolamides as ATP Competitive DNA Gyrase B Inhibitors: Design, Synthesis, and Evaluation

Bacterial DNA gyrase is a well-known and validated target in the design of antibacterial drugs. However, inhibitors of its ATP binding subunit, DNA gyrase B (GyrB), have so far not reached clinical use. In the present study, three different series of N-ph

Pyrrolidinyl phenylurea derivatives as novel CCR3 antagonists

Optimization starting with our lead compound 1 (IC50 = 4.9 nM) led to the identification of pyrrolidinyl phenylurea derivatives. Further modification toward improvement of the bioavailability provided (R)-1-(1-((6-fluoronaphthalen-2-yl)methyl)pyrrolidin-3-yl)-3-(2-(2- hydroxyethoxy)phenyl)urea 32 (IC50 = 1.7 nM), a potent and orally active CCR3 antagonist.